Intelligence Platform

Patents

Browse 2,465 pharma-relevant patents (US and EP, A61K/A61P) linked to tracked companies. Patent cliff and LOE intelligence for BD teams.

29,054 patents indexed

patent

US 8569379

Use of rasagiline for the treatment of olfactory dysfunction

TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted Tue Oct 29 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 24 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8569448

NMDAR biomarkers for diagnosis and treatment of traumatic brain injury and other disorders

GRACE LABORATORIES, LLC · Granted Tue Oct 29 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 24 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8568977

Compositions and methods for diagnosis and treatment of tumors

The United States of America as Represented by the Secretary of the Department of Health and Human Services · Granted Tue Oct 29 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 24 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8569225

Targeting complement factor H for treatment of diseases

The Regents of the University of Colorado, a Body Corporate · Granted Tue Oct 29 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 24 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8569320

Topical composition for the treatment of actinic keratosis

Almirall Hermal GmbH · Granted Tue Oct 29 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 24 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8563595

Treatment of cancer with complex organic-inorganic pigment compositions

The Board of Regents of the University of Texas System · Granted Tue Oct 22 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 17 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8557298

Medicaments for chemotherapeutic treatment of disease

Provectus Pharmatech, Inc. · Granted Tue Oct 15 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 10 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8557290

Multifunction nanoconjugates for imaging applications and targeted treatment

Northwestern University · Granted Tue Oct 15 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 10 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8541373

BChE albumin fusions for the treatment of cocaine abuse

TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted Tue Sep 24 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 19 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8541403

Dihydropyridophthalazinone inhibitors of poly(ADP-ribose)polymerase (PARP) for use in trea

BIOMARIN PHARMACEUTICAL INC. · Granted Tue Sep 24 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 19 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8541456

Roflumilast for the treatment of diabetes mellitus type 2

TAKEDA GMBH · Granted Tue Sep 24 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 19 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8541371

Treatment of conditions related to cecal ligation shock

The Regents of the University of California · Granted Tue Sep 24 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 19 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8536148

Disabling autophagy as a treatment for lysosomal storage diseases

The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Sep 17 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 12 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8530466

Use of 2,4-pyrimidinediamines for the treatment of atherosclerosis

Rigel Pharmaceuticals, Inc. · Granted Tue Sep 10 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 05 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8524655

Use of SCF and G-CSF in the treatment of cerebral ischemia and neurological disorders

Northwestern University · Granted Tue Sep 03 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 29 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8518390

Treatment of stroke and other acute neural degenerative disorders via intranasal administr

Advanced Technologies and Regenerative Medicine, LLC · Granted Tue Aug 27 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 22 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8518870

Compositions and methods for cancer treatment using targeted carbon nanotubes

The Board of Regents of the University of Oklahoma · Granted Tue Aug 27 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 22 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8518980

Treatment of Duchenne muscular dystrophy

Summit Corporation Plc · Granted Tue Aug 27 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 22 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8512964

Targets for treatment of hypercholesterolemia

The Regents of the University of California · Granted Tue Aug 20 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 15 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8506959

Prevention and treatment of synucleinopathic and amyloidogenic disease

The Regents of the University of California · Granted Tue Aug 13 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 08 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8507447

Treatments for gastrointestinal disorders

IRONWOOD PHARMACEUTICALS, INC. · Granted Tue Aug 13 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 08 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8501713

Drug combinations for the treatment of duchenne muscular dystrophy

Summit Corporation Plc · Granted Tue Aug 06 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 01 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8501740

Methods of treatment of opioid tolerance, physical dependence, pain and addiction with inh

The Board of Regents of the University of Texas System · Granted Tue Aug 06 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 01 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8501766

Treatment of rheumatoid arthritis with a combination of laquinimod and methotrexate

TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted Tue Aug 06 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 01 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

granted